Immunostimulating vector system
AssigneeProvecs Medical GmbH
InventorsFrank Schnieders, Andrea Miegel, Carolin Biermann-Fleischhauer
Life of this patent
Estimating the term…
Abstract
A method of treating cancer, a viral infection and/or an immune system disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a vector, wherein the vector comprises (a) nucleic acid sequences encoding 4-1BB ligand (4-1BBL), single chain IL-12 (scIL-12) and IL-2, and (b) at least one regulatory nucleic acid sequence providing for an increased expression level of 4-1BBL as compared to the expression levels of scIL-12 and IL-2, and other related methods.
Claims4
A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a vector, wherein the vector comprises the nucleotide sequence of SEQ ID NO:
- 12, which comprises nucleic acid sequences encoding 4-1BB ligand (4-1BBL), single chain IL-12 (scIL-12) and IL-2, and wherein the administration is intratumoral administration.
Dependencies are inferred from the claim text.